The Japanese yen faces new risks. Strategists worry that the Bank of Japan may wait until March or later to raise interest rates. A new risk is emerging for the Japanese yen. Foreign exchange strategists in Tokyo warn that the Bank of Japan may wait until March or later next year to raise interest rates. On Wednesday, the market tasted this danger, and the yen fell to its lowest level in more than two weeks as traders responded to a Bloomberg report that the Bank of Japan is known to think that it is no harm to raise interest rates later. The yen only fell to 152.82 against the dollar, and the market is still debating whether the Bank of Japan will take action at its next meeting on December 19 or about a month later. Shusuke Yamada, head of Japan's foreign exchange and interest rate strategy at Bank of America in Tokyo, said that if policymakers put off raising interest rates for a longer time, the situation would be very different. "If the interest rate hike is postponed until March, the yen carry trade is likely to make a comeback," Yamada said on Thursday. "The yen is likely to fall again to a level just below the 157 mark hit in 155 or November."In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)On the 12th, South Korea's National Assembly voted to pass a special civil strife inspection law to investigate President Yin Xiyue's suspicion of civil strife. (Xinhua News Agency)
The State Council agrees in principle with the Master Plan of Fuzhou Land and Space (2021-2035), and the State Council agrees in principle with the Master Plan of Fuzhou Land and Space (2021-2035) approved by the Ministry of Natural Resources. By 2035, the cultivated land in Fuzhou will be no less than 1,421,300 mu, of which the permanent basic farmland protection area will be no less than 1,267,200 mu; The red line area of ecological protection is not less than 5082.05 square kilometers, of which the red line area of marine ecological protection is not less than 2671.73 square kilometers; The border area of urban development is controlled within 1000.63 square kilometers; The use area of construction land per unit GDP decreased by not less than 40%; The retention rate of natural coastline on the mainland is not lower than the tasks assigned by the higher authorities, of which it will be not lower than 40.31% in 2025; The total water consumption shall not exceed the indicators issued by the higher authorities, including 2.80 billion cubic meters in 2025; Except for major national projects, reclamation is completely prohibited; Strictly manage uninhabited islands. Clarify the key prevention and control areas of natural disaster risks, delimit risk control lines such as floods and earthquakes, as well as green space system lines, water body protection lines, historical and cultural protection lines and infrastructure construction control lines, and implement safety guarantee spaces such as strategic mineral resources.Botuo Bio: Adjust the profit distribution plan for the first three quarters of 2024. Botuo Bio announced that the total amount of cash dividends to be distributed in the company's profit distribution for the first three quarters of 2024 was adjusted from RMB 52.2583 million to RMB 53.2083 million. Before the adjustment, the company's total share capital was 105 million shares after deducting the shares in the company's repurchase special securities account, and a total cash dividend of 52.2583 million yuan was planned to be distributed. After adjustment, the company's total share capital is 107 million shares, of which 250,000 shares are repurchased in the special securities account, and the total number of shares actually participating in the profit distribution of the company is 106 million shares, with a total cash dividend of 53,208,300 yuan.Mackler M, Governor of the Bank of Canada: (Regarding the potential tariff policy) We can't make policies based on what may happen. If the (US) tariffs are implemented as promised, it will cause serious damage to the Canadian economy.
Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.The monkeypox vaccine with independent intellectual property rights in China was approved for clinical use. On December 10th, the monkeypox vaccine jointly developed by China Bio-Beijing Institute of Biological Products and China Center for Disease Control and Prevention received the approval notice of drug clinical trial issued by National Medical Products Administration, and it was registered and classified as Class 1.2 innovative vaccine. The vaccine is an innovative vaccine independently developed by scientists in China with completely independent intellectual property rights, which is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in China. (China Biology)The 2.53 billion shares held by Greenland Group have been frozen. According to the legal litigation information of Tianyancha, recently, Guangxi Construction Engineering Group Co., Ltd. added a piece of information on the freezing of shares. The executor is Greenland Holding Group Co., Ltd., and the amount of frozen shares is about 2.53 billion RMB. The freezing period is from December 9, 2024 to December 8, 2027. The enforcement court is Wanzhou District People's Court in Chongqing.
Strategy guide 12-13
Strategy guide 12-13